Key result
Holding oral intake with weekly Evolocumab followed by long-term weight reduction and Fenofibrate safely and effectively prevented recurrence of hypertriglyceridemic acute pancreatitis over 2 years.
Case Report (n=1)
In a patient with type IIb familial hyperlipidemia and hypertriglyceridemic acute pancreatitis, acute management with evolocumab and long-term prevention with weight reduction and fenofibrate was safe and effective.
Answers are grounded in this paper and cite their sources.
May inform acute and preventive strategies in hypertriglyceridemic pancreatitis; leaves open confirmation in controlled trials.
Background: Acute pancreatitis (AP) is an inflammatory process affecting the pancreas. Hypertriglyceridemic AP (HTAP) is its third leading cause after gallstones followed by alcohol use. It develops when stars align viz. triggers (acquired surges) in patients with genetic hypertriglyceridemia. Case: severe and acute pancreatitis had developed in a 57-year-old man with type IIb familial hyperlipidemia after heavy fatty meals. The acute phase was controlled by holding oral intake with weekly Evolocumab therapy and long-term prevention by weight reduction and Fenofibrate alone. His pancreatic endocrine and exocrine functions remained normal after 2 years of follow-up. Conclusion: Those four measures were safe, practical and effective for short- and long-term management of HTAP.
No takes yet. Share an insight, caveat, or question.
El-Reshaid et al. (2024) conducted a case report in Hypertriglyceridemic acute pancreatitis (n=1). Evolocumab, Fenofibrate, and weight reduction was evaluated on Recurrence of clinical pancreatitis. Holding oral intake with weekly Evolocumab followed by long-term weight reduction and Fenofibrate safely and effectively prevented recurrence of hypertriglyceridemic acute pancreatitis over 2 years.
Synapse has enriched 10 related papers. Consider them for comparative context: